Simplified Negative and Positive Symptoms Interview (SNAPSI) Resources

Research and measure-based care of schizophrenia and related disorders requires a highly efficient assessment that works in clinical settings. Clinicians, including physicians, nurses, social workers, and other allied health professionals need to be able to gather data to support several ratings simultaneously, and be useful across clinical disciplines (psychiatry, nursing, social work, etc)., To meet this need, we have developed the Simplified Negative and Positive Symptoms Interview (SNAPSI).

The primary purpose of the SNAPSI is to facilitate quick and valid rating on the 6-item version of the Positive and Negative Syndrome Scale (PANSS-6), and other measures such as; the Brief Psychiatric Rating Scale (BPRS), the Brief Negative Symptom Scale (BNSS), the Clinical Global Impression-Severity (CGI-S) and Improvement (CGI-I) scales.

Click below to register and access the SNAPSI guide, available in 19 languages:

Access SNAPSI Resources

About the SNAPSI assessment

The SNAPSI is an assessment guide that includes probes and structures modeled on both standard semi-structured tools, such as the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, the BPRS, and Montgomery-Asberg Depression Rating Scale as well as newer tools for evaluation of negative symptoms, such as the Brief Negative Symptoms Scale (BNSS), the Negative Symptoms Assessment (NSA), and functional assessments, such as the Personal and Social Performance Scale. For example, in addition to standard probes for delusional ideas, and hallucinations, a section that asks the participant to describe emotional states directly, and a section on task sequencing allows direct and more efficient evaluation of affect and thought disorder than passive observation. Additionally, a well-integrated assessment section for caregivers adds an important component, clearly delineating how to evaluate collateral information from third-party sources.

In addition to enabling rating on scales such as the PANSS-6, SNAPSI can be used to:

  1. Collect information to rate selected items from the BPRS
  2. Supplement evaluations of negative symptoms, including those considered in the BNSS or the NSA
  3. Facilitate standardized rating on global severity rating scales such as the Clinical Global Impression – Severity (CGI-S) and Improvement (CGI-I) scales

The SNAPSI takes approximately 10-20 minutes to administer depending on the rater’s prior knowledge of the symptom severity. It is freely available for non-commercial clinical and academic use.

Access SNAPSI Resources

Clinical and Amyloid Screen Failure Rates in Episodic Memory Measures of Early AD Trials

This study examined two episodic memory measures – the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) and the Cogstate International Shopping List Test (ISLT) – to compare their clinical and amyloid screen failure rates in early AD trials.

Authors: S. Negash, C. Weber, C. Randolph

Presented at the 11th Clinical Trials on Alzheimer’s Disease (CTAD), Barcelona, Spain (October 2018)


Independent Telephone-based Assessment of Depressive Symptoms in China

A pilot study conducted at three hospitals in China studied remote independent administration of the Structured Interview Guide for the Montgomery-Asberg Depression Rating Scale (SIGMA) to determine the reliability of the MADRS when administered via telephone to Mandarin-speaking patients in China with Major Depression Disorder.

Authors: Gang WANG, Tianmei SI, Xiufeng XU, Jaskaran SINGH, Jessie HE, Cong LIU, Lawrence H. Yang, Honglan LI, Jianmin ZHUO, Mark Opler

Presented at The International Society for CNS Clinical Trials and Methodology (ISCTM) Autumn Conference, Marina Del Ray, CA (October 2018)


Error Rates and Data Integrity: eCOA versus Paper Administration of the PANSS

Methodological Question: Does the use of electronic clinical outcomes assessment (eCOA) impact rates of scoring errors as evaluated with the ISCTM working group consensus method for PANSS data?

Among the Conclusions: eCOA administrations of the Positive and Negative Syndrome Scale (PANSS) are less susceptible to scoring inconsistencies and error compared to those administered on paper.

Authors: S. Negash, G. Capodilupo, B. Echevarria, M. Opler

Presented at The International Society for CNS Clinical Trials and Methodology (ISCTM) Autumn Conference, Marina Del Ray, CA (October 2018)


Independent and Site-based Ratings of Symptom Severity in Pharmacogenetics Clinical Trials

Personalized medicine and pharmacogenomics hold strong promise for psychiatry. Studies in this area require novel approaches to ensure endpoint reliability and validity, reduce the impact of treatment unblinding, and minimize other confounds that reduce signal detection. At the American Psychiatric Association Annual Meeting, MedAvante-ProPhase presented analysis of a combination of novel assessment methods, including remote, independent ratings, to evaluate adherence to inclusion criteria and efficacy in pharmacogenetics clinical trials.

Download Poster

Reliability Findings from the Unified Global Training Program for the Brief Negative Symptoms Scale (BNSS)

MedAvante-ProPhase presented an analysis of reliability in administration of the Brief Negative Symptoms Scale (BNSS) across multiple studies and countries at the 14th International Society for CNS Clinical Trials and Methodology (ISCTM) Scientific Conference. BNSS achieved overall good-to-excellent inter-rater reliability among raters from different countries and cultures.

Continue reading